"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
Descriptor ID |
D007093
|
MeSH Number(s) |
D03.383.129.308
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1996 | 0 | 1 | 1 |
1997 | 1 | 2 | 3 |
1998 | 1 | 2 | 3 |
1999 | 3 | 1 | 4 |
2000 | 0 | 2 | 2 |
2001 | 1 | 6 | 7 |
2002 | 2 | 6 | 8 |
2003 | 4 | 7 | 11 |
2004 | 7 | 7 | 14 |
2005 | 9 | 9 | 18 |
2006 | 8 | 8 | 16 |
2007 | 8 | 8 | 16 |
2008 | 13 | 13 | 26 |
2009 | 13 | 9 | 22 |
2010 | 10 | 11 | 21 |
2011 | 13 | 9 | 22 |
2012 | 22 | 11 | 33 |
2013 | 24 | 12 | 36 |
2014 | 18 | 14 | 32 |
2015 | 20 | 20 | 40 |
2016 | 17 | 12 | 29 |
2017 | 15 | 11 | 26 |
2018 | 12 | 6 | 18 |
2019 | 7 | 13 | 20 |
2020 | 6 | 7 | 13 |
2021 | 4 | 6 | 10 |
2022 | 2 | 11 | 13 |
2023 | 0 | 3 | 3 |
2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.
-
Thyroid Cancer: A Review. JAMA. 2024 02 06; 331(5):425-435.
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. Cell Death Dis. 2024 01 22; 15(1):80.
-
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clin Breast Cancer. 2023 Dec; 23(8):e515-e522.
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
-
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 05; 29(5):1103-1112.
-
Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leuk Lymphoma. 2023 01; 64(1):79-86.
-
A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis. Int Heart J. 2022 Sep 30; 63(5):970-977.
-
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2022 12; 63(13):3154-3164.